Gastric and oesophageal cancer trials in Argentina

6 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

• Phase 2/3Taking people
  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  Where

  ABB, Buenos Aires, Ciudad Autónoma de Buenos Aires

  Age

  18 years and over

  People

  690 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07221149 · EU 2025-523263-37-00
• Phase 1/2Taking people
  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  Where

  Buenos Aires, Caba, Ciudad Autonoma Buenos Aires, Mar del Plata

  Age

  18 years and over

  People

  680 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT06330064 · EU 2023-509632-26-00
• Phase 3Taking people
  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  Where

  Buenos Aires, Ciudad Autónoma Buenos Aires, Ciudad de Buenos Aires, Rosario, Viedma

  Age

  18 years and over

  People

  840 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06764875 · EU 2024-512583-57-00
• Phase 3Taking people
  A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  Where

  CABA, Ciudad Autonoma Buenos Aires, La Rioja

  Age

  18 years and over

  People

  351 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT07043400 · EU 2025-522862-58-00
• Phase 3Taking people
  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  Where

  Buenos Aires, Córdoba, Mar del Plata, Rosario

  Age

  18 years and over

  People

  726 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT06731478
• Phase 3Taking people
  A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

  Where

  Buenos Aires, Cordoba, Córdoba, Puerto Alegre, Rosario, San Juan, San Miguel de Tucumán, San Pablo, Viedma

  Age

  18 years and over

  People

  550 worldwide

  Run by

  Shanghai Henlius Biotech

  See details and how to joinNCT06532006 · EU 2024-516633-12-00